Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

AstraZeneca, Alexion's mysathenia gravis treatment enters crowded market

AstraZeneca and Alexion won FDA approval Monday for their self-administered generalized myasthenia gravis (gMG) drug Klygefa. The drug, also known as gefurulimab, is a once-weekly treatment for patients who have anti-acetylcholine receptor antibodies, a harmful ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Finance & Markets

More from Monday 16 November →